MacroCure is a biotechnology company focused on the development and commercialization of advanced cell therapy products. The company's first focus of interest is in the arena of wound care. The technology employs activated white blood cells obtained from young adults healthy donor blood. The activated cells provide the natural environment for wound healing, and ensure that necessary cell activities and factor secretions are maintained as required for wound healing. This novel concept is the first of its kind in the field of wound therapy.
MacroCure currently manufactures and markets its lead product, CureXcell™, in Israel for hard-to-heal wound treatment. The cell therapy company has its regulatory strategy in place for market approval in North America and Europe.
CureXcell™ demonstrated favorable results for standard of care (SOC) when treating various chronic wounds. Clinical trials in Israel have shown a 90% reduction of the mortality rate in patients with deep sternal wound infections and a markedly improved healing rate for severe pressure ulcers. Since the introduction of CureXcell™ to the market, more than 4,000 patients have been treated in Israel with this advanced cell therapy. No serious adverse events have been reported.